WARNING! The Omicron Is Evolving Rapidly And Big Pharma Is Providing Opportunities For It To Do So! New York Study Shows BA.1.1 And BA.2 Evolved As Such!
While the WHO, CDC, ECDC and all those controlling the COVID-19 narratives including the Biden administration are now controlling data about emerging SARS-CoV-2 variants both on online sites sharing genomic sequencings and also the release of such studies into journals, so has to not disrupt their vaccine, monoclonal drugs and ineffective but dangerous antiviral drugs agendas, more SARS-CoV-2 variants are emerging not only in the Delta variant family and even in newer lineages but also in the Omicron variant. It is completely wrong to say that there is only four Omicron variants that have emerged to date ie the BA.1, BA.1.1, BA.2 and BA.3 as in reality another 3 more major and concerning Omicron sub-lineages have emerged and also many more sub-lineages that have emerged but not yet predominant in circulation.
Forget about asking any of the rude and arrogant British so-called virology or genomic ‘experts’ for their opinions or validation as most of these ‘bastards’ are under the payroll of the big pharma!
But what is concerning is that most of these new emerging Omicron variants are evolving to not only evade natural and vaccine induced immunity but also developing resistance to the drugs being used including the various monoclonal drugs and also the new antiviral pills recently introduced. In fact, prematurely we can say that it is all these therapeutics that is fueling more mutations and variants to arise and more studies are needed to validate this.
Thailand Medical News
had published two articles on two new Omicron sub-lineages that have emerged from the BA.1 and BA.2 variants, one in Brazil and another Denmark despite being warned not to do so by certain entities trying to control the COVID narratives.
Now researchers from Columbia University Vagelos College of Physicians and Surgeons-New York have in a new study also found that the newer Omicron variants such as the BA.1.1 ie BA.1 with an R346K mutation (BA.1+R346K) and B.1.1.529.2 (BA.2) containing 8 unique spike mutations while lacking 13 spike mutations found in BA.1, have all evolved to evade immunity induced by various therapeutic drugs.
The identification of the Omicron variant (B.1.1.529.1 or BA.1) of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in Botswana in November 20211 immediately raised alarms due to the sheer number of mutations in the spike glycoprotein that could lead to striking antibody evasion.
The study team and also other researchers had already previously published study findings confirming such a concern.
Further surveillance of Omicron evolution has since revealed the rise in prevalence of two sublineages, BA.1 with an R346K mutation and BA.2.
The study team therefore extended their studies to include antigenic characterization of these new sublineages. Polyclonal sera from patients infected by wild-type SARS-CoV-2 or recipients of current mRNA vaccines showed a substantial loss in neutralizing activity against both BA.1+R346K and BA.2, with drops comparable to that already reported for BA.1.
These study findings indicate that these three sublineages of Omicron are antigenically equidistant from the wild-type SARS-CoV-2 and thus similarly threaten the efficacies of current vaccines.
Importantly, BA.2 also exhibited marked resistance to 17 of 19 neutralizing monoclonal antibodies tested, including S309 (sotrovimab), which had retained appreciable activity against BA.1 and BA.1+R346K2.
This study finding shows that no presently approved or authorized monoclonal antibody therapy could adequately cover all sub-lineages of the Omicron variant and perhaps the use of these drugs are driving the mutations.
The study findings were published on a preprint server and are currently being peer reviewed. https://www.biorxiv.org/content/10.1101/2022.02.07.479306v1
Ever since the emergence of the SARS-CoV-2 Omicron variant (B.1.1.529) in November 2021, the COVID-19 health crisis has further exacerbated as the novel variant exhibits additional pathogenic features compared to the wildtype (WT) virus.
Detailed surveillance studies on the evolution of the Omicron variant reveal a declining proportion of BA.1 lineage (the original form of Omicron) in circulation.
Concurrently, the prevalence of two Omicron sub-lineages ie BA.1.1 and BA.2 has increased but many more newer BA.1 And BA.2 sub-lineages are emerging and gradually gaining predominance in circulation.
The sub-lineage (BA.1 + R346K) carries an extra R346K mutation than the BA.1 lineage, and the other sub-lineage (BA.2) has eight unique substitutions and lacks 13 spike mutations of the BA.1 lineage. The BA.1 lineage and its sub-lineages (BA.1 + R346K and BA.2) have 21 common mutations while the BA.1 lineage harbor 13 unique substitutions.
The study team investigated the antigenic characteristics of the Omicron sublineages. The neutralization activity of polyclonal sera from individuals infected with WT SARS-CoV-2 and messenger ribonucleic acid (mRNA) vaccine recipients (including boosted individuals) against the sublineages was determined.
Neutralization activity was also determined against the WT (D614G) pseudovirus.
Around 19 monoclonal antibodies directed at either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the SARS-CoV-2 spike protein were included as probes to examine their sensitivity to the Omicron sublineages.
Interestingly sera from both infected and vaccinated persons showed lower neutralizing potential against the two sublineages, which is consistent with previous reports of reduced neutralization potency of sera against the BA.1 lineage.
The study team observed that neutralizing titers for many samples were below the limit of detection (LoD). Sera from individuals who had been administered with a booster dose showed better neutralizing titers against the sublineages than that from doubly vaccinated subjects. The mean neutralization titers of sera against the sublineages were lower than that for D614G or WT SARS-CoV-2.
The study team observed that 17 MAbs had either lost neutralization activity against the BA.2 sublineage or were severely impaired to neutralize it, which is similar to earlier results for the BA.1 lineage by the same research team.
Importantly all MAbs from RBD class 4 demonstrated a higher loss of neutralization against BA.2 as compared with the BA.1 + R346K sublineage.
The monoclonal drug Sotrovimab or S309, a MAb approved for clinical use against the Omicron (BA.1) variant, had the most prominent loss of neutralization with a 27-fold decrease against the BA.2 sublineage.
One RBD class 3 MAb, Ly-CoV1404 or bamlanivimab, was found to neutralize all Omicron sublineages. COV2-2130, or, cilgavimab was found to neutralize BA.2 and a combination of cilgavimab and tixagevimab (COV2-2196), too, retained neutralization potency against BA.2.
It will be interesting to see when newer Omicron sub-lineages will emerge as these drugs are being used now in certain countries.
It was also found that each of the eight unique mutations observed in BA.2 were introduced into separate pseudoviruses and tested with MAbs.
Significantly, the S371F mutation of BA.2 negatively affected the activity of many RBD MAbs similar to the S371L substitution of the BA.1 lineage. The S371F mutation has been speculated to be responsible for the observed loss of sotrovimab potency against BA.2. The team also observed that another mutation (D405N) in the BA.2 sublineage had adverse effects on the activity of the CB6 antibody.
Importantly, the study findings show that polyclonal sera from convalescent and vaccinated people had lower neutralization activity against the sublineages of the Omicron variant comparable to that reported against the BA.1 lineage.
The study team proposed that all sublineages were antigenically equidistant from WT SARS-CoV-2 and thereby could comparably affect the established efficacies of available vaccines.
The study findings also highlighted important observations and noted that none of the approved therapeutic antibodies could neutralize all Omicron sublineages, raising suspicions over the validity of current therapies.
The MAbs with neutralizing activity against BA.2 that are currently being introduced or use in certain countries will ultimately lead to more Omicron sublineages.
Already unknown to many, many sublineages of the current VOCs have already emerged that are drug resistant to remdesivir. https://www.medrxiv.org/content/10.1101/2021.11.08.21266069v2
The virus has even developed resistance to even ivermectin! (Note that ivermectin only had a certain degree of efficacy against the initial wildtype strain but is totally infective against the later variants and is no better than a placebo or in some cases even acts as a nocebo!
Researchers are also worried that the current oral antivirals such as Paxlovid and Molnupiravir will ultimately lead to drug resistant strains emerging. https://www.ema.europa.eu/en/documents/referral/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution_en.pdf
However Thailand Medical News
predicts that despite the rising number of Omicron sublineages, the next more lethal and catastrophic surge expected to start anytime around late March to early May will not be led by an Omicron variant or sublineage but most likely a recombinant variant involving a newer Delta sub-variant with either another zoonotic coronavirus or with one of the existing pathogenic viruses that affects humans ie herpes or HIV!
For more on emerging Omicron sublineages
, keep n logging to Thailand Medical News.